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ABSTRACT
The straightforward production and dose-controlled
administration of protein therapeutics remain major
challenges for the biopharmaceutical manufacturing
and gene therapy communities. Transgenes linked to
HIV-1-derived vpr and pol-based protease cleav-
age (PC) sequences were co-produced as chimeric
fusion proteins in a lentivirus production setting,
encapsidated and processed to fusion peptide-free
native protein in pseudotyped lentivirions for intra-
cellular delivery and therapeutic action in target
cells. Devoid of viral genome sequences, protein-
transducing nanoparticles (PTNs) enabled transient
and dose-dependent delivery of therapeutic proteins
at functional quantities into a variety of mammalian
cells in the absence of host chromosome modifica-
tions. PTNs delivering Manihot esculenta linamarase
into rodent or human, tumor cell lines and spheroids
mediated hydrolysis of the innocuous natural pro-
drug linamarin to cyanide and resulted in efficient
cell killing. Following linamarin injection into nude
mice, linamarase-transducing nanoparticles impac-
ted solid tumor development through the bystander
effect of cyanide.
INTRODUCTION
Therapeutic interventions that complement molecular
deficiencies through the application of protein pharmaceuti-
cals are the cornerstone of modern medicine (1). While
the biopharmaceutical manufacturing industry focuses on
production and regular administration of protein therapeutics
(1), the gene therapy community capitalizes on therapeutic
transgene delivery for sustained reversion of genetic defects
(2). Although several protein therapeutics have been clinically
licensed, downstream processing, delivery and pharmacoki-
netics continue to be major scientific and economic challenges
(1). Likewise for gene therapy, advances in designing efficient
viral systems for chromosomal transgene integration (3), and
progress in expression dosing (4) are overshadowed by safety
concerns associated with inadvertent tumor formation result-
ing from unspecific integration into non-malignant cells as
evidenced in the first human trials (2,5,6).
For transient delivery of therapeutic transgenes, pseudo-
transduction (7,8), non-viral transfection technologies (9)
and episomal vectors (10) have been designed. Non-genetic
approaches for therapeutic delivery include directly delivered
therapeutic macromolecules using polymer- and liposome-
based drug-delivery systems (8), and trojanic fusion peptides
which transfer proteins into mammalian cells by an unknown
energy- and receptor-independent mechanism (11).
With a global mortality rate of 12%, malignant tumors are
amongst the most severe of human pathologies, and therefore
cancer therapy continues to be a priority for biopharmaceutical
manufacturing and gene therapy societies (1,12). A number of
strategies have been developed in the past to sensitize tumor
cells to specific prodrugs. One of the most successful
approaches is the Herpes simplex thymidine kinase
(HSVtk)—ganciclovir system in which HSVtk-mediated
phosphorylation of nucleoside analogs, including ganciclovir,
blocks DNA replication (13). Another technology is based
upon the natural linamarase—linamarin prodrug system
which has evolved as a defense mechanism against insect
herbivores in Cassava (Manihot esculenta) plants (14).
Damage of the Cassava cell walls by insect larvae releases
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the b-glucosidase linamarase which is stored in the plant cell
vacuoles. Linamarase hydrolyses the extracellular innocuous
cyanogenic glucoside substrate linamarin into glucose, ace-
tone and gaseous cyanide thereby mediating efficient cell kill-
ing (15). As linamarin is not hydrolyzed by most mammalian
tissues, it remains innocuous (LD50, 300 mg/kg body weight)
and is readily excreted through the urine (15–17).
We have combined classic transient transfection-based pro-
tein production with in situ encapsidation into engineered
nucleic acid-free nanoparticles to enable transient and dose-
controlled intracellular delivery of protein pharmaceuticals
into mammalian cells and mice. This protein transduction
technology combines the best features of biopharmaceutical
manufacturing (e.g. ease of protein production) and gene ther-
apy (e.g. efficient transduction) without sharing their major
disadvantages, such as unpredictable pharmacokinetics and
transgene-chromosome cross-talk resulting from random
proviral integration.
MATERIALS AND METHODS
Vector design
The helper plasmid pWW203 encoding a deficient integrase
(D64E mutation) was constructed by PCR-mediated
amplification of pCD/NL-BH* (18) (primers: OWW101: 50-
gtccaggaatatggcaactCgaGtgtacacatttagaagg-30 and OWW102:
50-ccttctaaatgtgtacaCtcGagttgccatattcctggac-30; annealing
sequence lowercase, mutations uppercase) using the
QuikChange kit (Stratagene, La Jolla, CA). pWW240
(PhEF1a-VPR-PC-pABGH) contains a PCR-amplified HIV-1-
derived VPR-PC (PC, pol-derived protease cleavage site)
fusion peptide [primers: OWW120: 50-GCGCGCCCAccatg-
gaacaagccccagaag-30 and OWW121: 50-GCTAGCGtctt-
gggccttatctattccatc-30; template: pLR2P-R-PC-IN (7)] which
was ligated in sense orientation into pEF6/V5-HIS-TOPO
(Invitrogen, Carlsbad, CA). pWW315 (PhEF1a-VPR-PC-
LIS-HA-pABGH) was constructed by NheI/NotI-mediated
in-frame cloning of the PCR-amplified [primers: OWW308:
50-GCCTAGCTAGCatgctcgtcttgttcataagc-30 and OWW309:
50-ATAGTTTAGCGGCCGCCTAAGCGTAATCTGGAAC-
ATCGTATGGGtacatcacatagaatttgccaacc-30; template:
pLlisSP (19)] and hemaglutinin A (HA)-tagged Cassava
(M.esculenta) linamarase (LIS) 30 of pWW240-encoded
VPR-PC. pWW326 (PhEF1a-VPR-PC-RIPDD-HIS-pABGH)
was constructed by restricting PCR-amplified [primers:
OWW310: 50-GCCTAGCTAGCatggactacaaagacgatgacg
and OWW319: 50-GCTCTAGAGCAAGCTTTTAATGGT-
GATGATGgttctggctgacgtaaatca-30; template: pRIPDD
(20)] and hexahistidine (HIS)-tagged human RIP death
domain (RIPDD) with NheI (cuts RIPDD fragment
50 while 30 end remains blunt) and replacing LIS of
pWW315 by RIPDD (NheI/EcoRV). pNLK8 (PhEF1a-GFP-
HIS-pABGH) was designed by SalI/MluI-mediated cloning of
PCR-amplified green fluorescent protein (GFP) [primers:
ONLK6: 50-ACGCGTCGACGCTAGcatggtgagcaagggcga-
gga-30 and ONLK7: 50-CGACGCGTGCAAGCTTGCGG-
CCGCTTAATGGTGATGGTGATGATGcttgtacagctcgtccat-
gcc-30; template: pMF365 (21)] into the corresponding
sites (SalI/MluI) of pBM43 (21). For construction of
pNLK9 (PhEF1a-VPR-PC-GFP-HIS-pABGH) GFP-HIS was
excised from pNLK8 by NheI/NotI and cloned into the
corresponding sites (NheI/NotI) of pWW240. pNLK11
(PhEF1a-VPR-PC-HSVtk-HA-pABGH) harbors PCR-amplified
(primers: ONLK8: 50-GCCTAGCTAGCatgcccacgctactgcgg-30
and ONLK9: 50-ATAGTTTAGCGGCCGCCTAAGCGTAAT-
CTGGAACATCGTATGGGcagttagcctcccccatctc-30; template:
pWW204, W. Weber unpublished data) and HA-tagged
HSVtk cloned 30 in-frame (NheI/NotI) of pWW240-encoded
VPR-PC.
Cell culture
Human embryonic kidney [HEK293-T; (21)], human breast
adenocarcinoma (MCF7; ATCC HTB-22) and human fibro-
sarcoma (HT-1080; ATCC CCL-121) cells were cultivated
in DMEM; Invitrogen supplemented with 10% heat-
inactivated fetal calf serum (FCS) (PAN biotech GmbH;
Aidenbach, Germany; Cat. No. 3302-P231902, Lot. No.
P231902) at 37C in a 5% CO2-containing humidified atmo-
sphere. Likewise, Chinese hamster ovary cells (CHO-K1;
ATCC CCL-61) were cultivated in FCS-containing FMX-8
(Cell Culture Technologies GmbH; Lugano, Switzerland)
and mouse mammary gland cells (4T1; ATCC CRL2935)
in FCS- and L-glutamine (2 mM) supplemented RPMI 1640
medium. Tumor spheroids were generated by gravity-enforced
self-assembly following cultivation of 1000 MCF7 or 3000
4T1 cells in hanging drops containing DMEM supplemented
with 20% KnockOut Serum Replacement (Invitrogen; Cat.
No. 10828-028) (22). For qualitative viability analysis of
cells in entire tumor spheroids, the microtissues were washed
twice in phosphate-buffered saline (PBS) and incubated for
5 min in ethidium bromide (0.0125% in H2O)—fluorescein-
diacetate (0.0005% in H2O) solution before the spheroids
were visualized by fluorescence microscopy (Leica DM-RB
equipped with a DC300 FX camera; Leica Microsystems
AG, Heerbrugg, Switzerland). Cell number and viability of
cell suspensions generated from monolayers (5 min incubation
in 0.5 ml prewarmed Trypsin/EDTA solution [PAN
Biotech GmbH], addition of 2 ml DMEM) and spheroid
cultures (pooling of 120 spheroids, 1· washing in PBS,
5 min incubation in 0.5 ml non-enzymatic cell dissociation
solution [Sigma Chemicals] under rigorous shaking at 37C,
5 min incubation in 0.5 ml prewarmed Trypsin/EDTA
solution while pipetting up and down and addition of 5 ml
DMEM) were quantified using a Casy1 cell counter
(Schaerfe System GmbH, Reutlingen, Germany; Analyzer
System Version 4.0).
Production of protein-transducing nanoparticles (PTNs)
PTNs were produced, quantified and characterized according
to protocols established for small-scale lentivirus production
(23). In brief, a DNA mixture containing (i) the vesicular
stomatitis virus G protein-encoding pLTR-G (5 mg) for
PTN pseudotyping, (ii) the helper construct pWW203
(5 mg) providing PTN assembly functions in trans and (iii)
a product vector (10 mg) (e.g. pWW315, linamarase;
pWW326, RIPDD; pNLK9, GFP; pNLK11, HSVtk) encoding
the desired heterologous protein in an encapsidation-
competent format (pNLK8, GFP as encapsidation-
incompetent control) were transiently transfected into
HEK293-T (2.5 · 106) (23). PTNs (typically 1 · 106 c.f.u.)
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were collected from the culture supernatant (10 ml) 60 h after
transfection by filtration (0.45 mm; Schleicher & Schuell
GmbH, Dassel, Germany) and centrifuged for 3.5 h at
4C (Beckman LM-8 ultracentrifuge, Ti50.2 rotor, 70 000 g,
optiseal tubes; Beckman Instruments Inc., CA). The PTN
pellet was resuspended in 600 ml FCS-supplemented
DMEM for titer quantification (23) (p24-specific enzyme-
linked immunosorbent assay (ELISA); Immunodiagnostics
Inc., Bedford, MA), application or cryopreservation at
80C. Following determination of viral p24 antigen, the
quantity of viral particles was calculated as follows:
The HIV-1 capsid consists of up to 2000 p24 proteins
(MW ¼ 25 550 g/mol) (24,25). Therefore, the viral quantity
was calculated as particles [particles/ml] ¼ p24 amount
[mg/ml] · 1 · 106 · [Avogadro/(25 550 · 2000)]. Subse-
quently, the GFP content of the PTN batch was determined
by western blot analysis. Specifically, varying amounts of
both p24 (ranging from 1.8 to 0.06 mg) and a GFP-His stan-
dard (ranging from 0.6 to 0.03 mg) were loaded for PAGE.
The intensity of western blot signals of PTN-packaged
GFP was quantified by comparison with the GFP standard
using a ChemiLux imager (Intas Science Imaging
Instruments GmbH, Go¨ttingen, Germany) with Gel-Pro Ana-
lyzer software installed (version 4.5; Media Cybernetics, Inc.,
Silver Spring, MD). The average ratio of GFP proteins
per particle was then calculated from the quantified PTN
and GFP concentrations.
Administration of PTNs, linamarin application, cyanide
quantification and western blot analysis
Monolayer (T25 flask; TPP, Trasadingen, Switzerland;
3 · 105 cells) and spheroid (MicroWell MiniTray, Nunc
GmbH, Wiesbaden, Germany; 1 spheroid [MCF7: 1000
cells/spheroid; 4T1: 3000 cells/spheroid]) cultures were
typically transduced with PTNs at a MOI of 9. 24 h (48 h
for 4T1) after seeding/aggregation cells were treated with
linamarin (2-OH-isobutyronitrile-b-D-gluco-pyranoside;
750 mg/ml in H2O, monolayers; 250 mg/ml H2O, spheroids;
TRC, Toronto, Canada) when indicated and the culture
flask/plate was sealed airtight for 48 h to prevent HCN evap-
oration during cultivation. Samples were stored at 20C and
cyanide was quantified using a modified protocol described
by Lambert and colleagues. In brief, solution A (oxidizing
reagent) was prepared by sequential dissolution of 5 g succin-
imide and 0.5 g N-chlorosuccinimide in 300 ml H2O with
subsequent dilution to 500 ml using H2O (storage at RT).
Solution B was generated by dissolution of 0.6 g barbituric
acid in 4 ml H2O, addition of 3 ml pyridine and subsequent
final dilution to 10 ml using H2O. Solution B was aliquoted
and stored at 20C. Immediately prior to use, 6 ml of
solution A was mixed with 120 ml of 1 M NaOH and
600 ml of 1 M acetic acid. To 224 ml of this mix was added
40 ml of culture medium sample and 40 ml amount of solution
B. The combined mixture was vortexed and incubated for
10 min at room temperature after which 100 ml aliquots
were transfered to a 96-well plate for spectrophotometric
analysis. Cyanide concentration was determined by measuring
absorption at 600 nm on a TECAN Genios PRO reader
(Tecan AG, Maennedorf, Switzerland) which was calibrated
using standardized sodium cyanide solutions (all chemicals
from Sigma, St Louis, MO). Western blot analysis was
performed as described previously (4) using HIS- and
HA-specific antibodies (Novagen, Madison, WI and Santa
Cruz Biotechnology, Santa Cruz, CA).
Animal experiments
Suspended 4T1 cells were adjusted in serum-free DMEM
to 1.2 · 106 cells/ml and 100 ml was subcutaneously injected
into female nude mice (Janvier CERT, Le Genest St Isle,
France). After 6 days developed tumors (6 mm diameter)
were measured using a sliding caliper before the mice were
treated twice daily (8 a.m. and 5 p.m.) by sequential intratu-
moral injection of 1 · 1010 linamarase-transducing nanopar-
ticles and 500 mg linamarin. Control mice received equal
amounts linamarase-transducing nanoparticles, but H2O
instead of linamarin. After 4 days, mouse sera were analyzed
for cyanide levels and tumor size was determined prior to
removal. Each data point represents the average of at
least 10 mice. All experiments involving animals were
approved by the French Ministry of Agriculture and Fishery
(C94-076-11) and performed at the Institute Gustave Roussy,
Paris, France.
Histology
Explanted tumors were fixed in 2% formaldehyde—0.9%
sodium chloride solution, washed twice in PBS and cryopre-
served in 70% EtOH for histologic analysis. Tumor samples
were embedded in paraffin and 3 mm slices generated by an
Ultracut device (Zeiss, Feldbach, Switzerland). Slices were
stained by haematoxylin/eosin and visualized by light
microscopy. Semi-thin sections were obtained at a nominal
thickness of 1 mm, stained with Toluidine blue, and
viewed under a Vanox BHS light microscope (Olympus
AG, Volketswil, Switzerland).
RESULTS
Design and characterization of PTNs
Production of protein-transducing lentiviral nanoparticles
required transient cotransfection of three complementary
plasmids into HEK293-T: (i) pLTR-G, which constitutively
produces the vesicular stomatitis virus G protein for particle
pseudotyping, (ii) pWW203, a helper plasmid which provides
proteins essential for particle formation and (iii) a constitutive
expression vector that encodes the protein of interest N-
terminally linked to a fusion peptide consisting of VPR and
the pol-derived 45 bp PC site which enables VPR-mediated
packaging and viral protease-mediated VPR-PC release result-
ing in encapsidation of the native heterologous protein
(Figure 1A). Following HEK293-T transfection with these
plasmids, heterologous fusion protein was produced, pro-
cessed and encapsidated into pseudotyped nucleic acid-free
lentivirions which transduced the native protein into target
cells (Figure 1B). Purified PTN samples were tested for poten-
tial residual carry-over of cytoplasmatic-derived transfected
plasmid DNA by PCR analysis which confirmed that tested
PTNs were nucleic acid-free (data not shown). VPR-PC-GFP
produced in HEK293-T localized mainly at specific structures
which are most likely particle assembly sites, while GFP
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pWW203 PhCMV GAG POL * VIF/VPR/REV/TAT/VPU pA
pLTR-G 5‘LTR VSV-G pA
pWW240 PhEF1α VPR PC pA
pNLK8 PhEF1α GFP pA
pNLK9 PhEF1α VPR PC GFP pA
pWW326 PhEF1α VPR PC RIPDD pA
pNLK11 PhEF1α VPR PC HSVtk pA
pWW315 PhEF1α VPR PC LIS pA
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Figure 1. Molecular configuration of PTNs. (A) Schematic representation of expression vectors required for the protein transduction technology. Transgenes are
drawn to scale. (B) Illustration of production and use of PTNs. (1) Transient cotransfection of (i) helper construct pWW203, (ii) pseudotyping vector pLTR-G, (iii)
heterologous protein-encoding lentivector (pPOI) into the PTN production cell line HEK293-T. (2) While pWW203- and pLTR-G-encoded proteins mediated
assembly of nucleic acid-free pseudotyped HIV-1-derived lentiviral nanoparticles (2a), the VPR-PC-tagged protein of interest (POI) was produced (2b) and targeted
to the lentivirions (2c), where the VPR-PC tag was released by the pol-encoded viral protease and the native POI was encapsidated into budding PTNs (2d). (3) PTNs
recovered from the culture supernatant were purified and concentrated by centrifugation and administered to target cells into which the POI was transduced (4).
Abbreviations: 50LTR, 50 long terminal repeat; GAG, HIV-1 gene encoding core proteins; GFP, green fluorescent protein; HSVtk, Herpex simplex virus type 1
thymidine kinase; LIS, Manihot esculenta (Cassava) linamarase; pA, polyadenylation site; PhCMV, human cytomegalovirus immediate early promoter; PhEF1a, human
elongation factor 1a promoter; RIPDD, RIP death domain—C-terminal domain of the human serine-threonine kinase 1 receptor; POL(*), gene encoding virion-
associated enzymes including [*] integration-deficient integrase; VSV-G, vesicular stomatitis virus G protein; VIF/VPR/REV/TAT/VPU, HIV-1 accessory proteins;
VPR, encapsidation-competent HIV-1-derived accessory protein; PC, pol-derived protease cleavage site.
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AB
C
Figure 2. Localization and encapsidation of VPR-PC-tagged heterologous proteins in HEK293-T producing PTNs. (A) Intracellular distribution of VPR-PC-
tagged and native GFP (scalebars 100 mm). (B) Fluorescence micrographs of pellets obtained by centrifugation of HEK293-T supernatants transfected with
helper plasmids pWW203 and pLTR-G and (i) pNLK9 (PhEF1a-VPR-PC-GFP-pA; 12 mg p24), (ii) pNLK8 (PhEF1a-GFP-pA; 17 mg p24) or (iii) no additional
vector, (12mg p24) (scalebar 500mm). (C) Western blot analysis of PTN-producing cell lysates (i) and HIS- (ii) or HA- (iii) tagged proteins in centrifugation-purified
PTN preparations equally adjusted to 135 ng p24. VPR-linked as well as processed native proteins are visualized (GFP, 28 kDa; RIPDD, 16 kDa; Herpes simplex
thymidine kinase [HSVtk], 37 kDa, Linamarase [Lis], 75 kDa). The 50 kDa signal in (iii) represents an unspecific interaction between a PTN protein and the HA
tag-recognizing antibody.
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AB
Figure 3. Impact of PTN-delivered linamarase-linamarin prodrug system on (tumor) cell viability 96 h after administration. (A) Light microscopy of monolayer
cultures treated with (i) linamarase-transducing nanoparticles (PTNLIS) and linamarin, (ii) PTNLIS only, (iii) linamarin only or (iv) empty control particles (scalebar
50 mm). (B) Viability of cells treated with PTNLIS and linamarin (Lin), Lin or PTNLIS alone or untreated as control (Cntrl).
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(pNLK8) lacking specific addresses were homogeneously dis-
persed into the cytosol (Figure 2A). GFP-transducing nanopar-
ticles were purified and concentrated by simple centrifugation
from which the bright fluorescence of encapsidated GFP in
particle pellets could be observed (Figure 2B). The lack of
GFP signal in purified samples originating from co-production
of particles and native GFP suggested that VPR-PC-GFP is
indeed packaged by the viral mechanism rather than by an
unspecific interaction with viral proteins (Figure 2B). Also,
western blot analysis showed partially processed full-length
VPR-PC-GFP fusion protein present in production cell
lysates and processed native fluorescent GFP in purified
PTNs (Figure 2C). Quantitative correlation of GFP fluores-
cence, western blot signal and lentivirion number indicated
that 2200 ± 340 GFP molecules were packaged into each
nanoparticle.
Validation of PTNs using prodrug systems
For PTN validation we focused on a drug-delivery system in
which toxic proteins were packaged and delivered in an
attempt to induce apoptosis in tumor cells. To that end, we
targeted the 120 amino acid RIPDD into lentiviral nanoparti-
cles (20). Although western blot analysis of pelleted particles
confirmed successful packaging and processing of RIPDD
(Figure 2C), it was difficult to isolate a sufficient number
of RIPDD-transducing nanoparticles due to efficient
RIPDD-triggered apoptosis in the producer cell line (data
not shown). Due to this problem, the initial strategy of directly
delivering apoptosis-triggering proteins was modified to a
prodrug-drug system consisting of HSVtk-transducing
nanoparticles which enable conversion of the prodrug ganci-
clovir into DNA replication-blocking nucleoside analogs (26).
As expected, the transient packaging cell line was not
impacted by VPR-PC-HSVtk. However, despite its accurate
targeting to lentivirions (Figure 2C), effective killing of trans-
duced and ganciclovir-treated tumor populations could not
be observed, probably due to the lack of a bystander effect
in this system (26) (data not shown).
In a second attempt to produce a viable (pro)drug system we
successfully targeted the 75 kDa VPR-PC-LIS linamarase
fusion protein into lentiviral nanoparticles (Figure 2C).
Linamarase-transducing nanoparticles were stable for at
least 48 h at room temperature as no cyanide production
was detected when encapsidated linamarase was incubated
with linamarin in a cell-free system (data not shown). How-
ever, co-application of linamarase-transducing nanoparticles
with linamarin resulted in cyanide production and effective
killing of rodent (CHO-K1, 4T1) and human (HT-1080,
MCF7) (tumor) cell lines (Figure 3A). Administration of
linamarin alone, or together with empty nanoparticles, did
not adversely impact cell viability, and cyanide content was
undetectable confirming that linamarase and lentivirions are
non-toxic, that no detectable auto-decomposition of linamarin
occurs and that the cells lack endogenous linamarase activity
(Figure 3B). At non-limiting and non-toxic linamarin con-
centrations of 750 mg/ml, cyanide production was cell type-
specific and showed a strong linear correlation between
the number of particles administered and the observed cyanide
concentration (Figure 4A). As exemplified in treated
CHO-K1 monolayer cultures, linamarase-mediated cyanide
production steadily accumulated in the culture medium until
cell killing was complete (Figures 3B and 4B; see movie in
Supplementary data).
Impact of linamarase-transducing nanoparticles on
tumor spheroids
Since results obtained with monolayer cultures may deviate
from those generated in tissues, we produced MCF7- and
4T1-derived solid state tumor-mimicking microtissues and
treated them with linamarase-transducing nanoparticles
prior to administration of linamarin. Microscopic analysis
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Figure 4. Cyanide production in CHO-K1 treated with a combination of
linamarase-transducing nanoparticles (PTNLIS) and linamarin. (A) Correlation
of PTNLIS number administered and the cyanide concentration produced in
CHO-K1 cultures after 72 h. (B) Cyanide production kinetics in PTNLIS-
transduced CHO-K1 cultures (5 · 108 PTN’s, 800 000 cells, 8 ml culture
medium).
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of treated tumor spheroids showed significant reduction of the
microtissues’ diameter after 120 h and global red fluorescence
after fluorescein-diacetate/ethidium bromide-based live/dead
staining which confirms that massive cell death had occurred
(Figure 5A and B; see also Figure 6). At 120 h, all tumor
spheriods were disaggregated for viability assessment of
individual cells which confirmed low cell viability in all
cyanide-treated groups regardless of whether cyanide was
directly applied or produced in situ by conversion of linamarin
(Figure 5C).
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Figure 5. Impact of PTN-delivered linamarase-linamarin prodrug system on 4T1-derived tumor spheroids. (A) Light and fluorescence (ethidium bromide, dead cells
shown in red; fluorescein-diacetate, viable cells shown in green) micrographs of 4T1-derived tumor spheroids treated up to 120 h with linamarase-transducing
nanoparticles (PTNLIS) plus linamarin, PTNLIS alone, NaCN or mock-transfected PTN production supernatants as control (Mock) (scalebar 200 mm). (B and C)
Quantitative analysis of 4T1- and MCF7-derived tumor spheroid diameters changes (B) and viability (C) 120 h after administration of PTNLIS/LIN, PTNLIS, NaCN or
linamarin as control (Lin).
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Functional linamarase transduction retards tumor
progression in mice
The 4T1 cells, which are commonly used as a human breast
cancer model in mice, were inoculated into nude mice to form
solid tumors. At a diameter of around 6 mm, DMEM contain-
ing either (i) a mixture of linamarin (500 mg) and 1.5 · 1010
linamarase-transducing nanoparticles, (ii) linamarase-
transducing nanoparticles only (1.5 · 1010) or (iii) sodium
cyanide (18 mg), were injected into the center of the tumor.
Control mice received only linamarin injections. Mice were
treated over 4 days after which blood samples were collected.
Tumor sizes were measured again prior to surgical removal
and blood serum samples were assessed for their cyanide
concentration. Although cyanide traces could be detected in
treated mice, which clearly indicated that cyanide injected or
generated by the transduced (pro)drug system in the tumor was
diffusing through the tissue into the blood system, the animals
did not show any signs of nausea. Within 4 days, tumors
treated with linamarase-transducing nanoparticles and lina-
marin or NaCN exhibited a significant decrease in tumor
growth when compared to linamarin-treated control tumors
(Figure 6A). In each group cyanide level was measured
(Figure 6B) and a correlation between decrease in tumor
growth and cyanide level was observed. Histologic analysis
of tumor tissue explants showed large lesions around the injec-
tion site which was consistent with cyanide-mediated killing
of both transduced and bystander cells. Increased lesions
observed for in situ-produced cyanide likely resulted from
constant high cyanide concentrations in the tumor (Figure 6C).
DISCUSSION
Protein pharmaceuticals enable transient dose-dependent
therapeutic interventions in the absence of genomic
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Figure 6. Tumor growth retardation in mice after administration of linamarin-transducing nanoparticles (PTNLIS) and linamarin (Lin). (A) Size of 4T1 tumors and
(B) serum cyanide levels of mice 4 days after injection of PTNLIS and Lin, PTNLIS alone, NaCN or Lin alone (Cntrl). (C) Histologic analysis of treated tumor explants
using haematoxylin–eosin (i,ii,iii and iv; sections; scalebar 400 mm) and toluidine blue (i0,ii0,iii0 and iv0; semi-thin sections; scalebar 20 mm) staining revealing the
effects of different treatment modalities versus control in 4T1 tumors. i and i0: Tumors treated by a combination of PTNLIS and linamarin showed a large necrotic area
around the application site. Black triangles indicate apoptotic figures and bodies at different stages of chromatin consolidation. ii and ii0: Treatment with PTNLIS alone
had practically no effect on the tumor growth. The blood vessels were preserved (black circles) and mitotic figures (black diamonds) were detectable close to the
application site. iii and iii0: Sodium cyanide injection had a pronounced effect only locally at the site of application as indicated by apoptotic profiles (black triangles).
At a distance lower than 250 mm of the application canal tumors exhibited normal cell morphology (black squares). iv and iv0: The tumor cells in the control group
treated by Lin demonstrated typical mitotic activity (black diamonds) and normal blood vessels (black circles) were formed.
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alterations, yet require sophisticated downstream processing
and specific formulations for optimal pharmacokinetics (1).
Viral gene therapy concepts which use advanced transgene
delivery systems may offer long-term correction of genetic
deficiencies, but expression dosing and random integration
into target chromosomes remain major challenges (27). We
have shown that PTNs could combine the best of both thera-
peutic strategies: (i) one-step transient production and pack-
aging of native therapeutic proteins of up to 75 kDa using
standard biopharmaceutical manufacturing technology, (ii)
one-step purification and concentration of encapsidated pro-
teins by simple centrifugation and (iii) cytosolic protein deliv-
ery without transduction of genetic information. Also, the
particle tropism could be modified for tissue-specific delivery
by pseudotyping (28) and PTNs may show improved pharma-
cokinetics as the protein therapeutic is protected from degrada-
tion en route to the target site. As demonstrated by the
production and functional delivery of the Cassava prodrug
system to eliminate tumor cells both in vitro and in vivo,
generic protein transduction systems have the potential to
provide affordable, safe and efficient medicines in the not-
too-distant future.
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